CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD
The clinical effectiveness in postoperative infections of sulbactam/cefoperazone (SBT/CPZ,(SBT 0.5g+CPZ 0.5g)×2/day) was compared to that of ceftizoxime (CZX, 1.0g×2/day) by a well controlled comparative study, to have the following results. 1. The overall effectiveness rate of SBT/CPZ and CZX as ju...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of antibiotics 1985/03/25, Vol.38(3), pp.643-670 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 670 |
|---|---|
| container_issue | 3 |
| container_start_page | 643 |
| container_title | Japanese journal of antibiotics |
| container_volume | 38 |
| creator | KOIKE, AKIHIKO MASAOKA, AKIRA MISHIMA, AKIRA MIZUNO, AKIRA SUZUKI, HIROSHI YURA, JIRO MATSUMOTO, KAZUAKI IRIYAMA, KEIJI KATO, KENICHI MATSUMOTO, KOICHI TAKESHIGE, KOTOHITO KATAOKA, MAKOTO ANDO, MASAHIDE FUJIOKA, MASAKI HORISAWA, MASUMASA KOHNO, MEGUMI SHINAGAWA, NAGAO OGAWA, NOBUYA ISHIKAWA, SHU ITO, TADAO KONDO, TATSUHEI |
| description | The clinical effectiveness in postoperative infections of sulbactam/cefoperazone (SBT/CPZ,(SBT 0.5g+CPZ 0.5g)×2/day) was compared to that of ceftizoxime (CZX, 1.0g×2/day) by a well controlled comparative study, to have the following results. 1. The overall effectiveness rate of SBT/CPZ and CZX as judged by Judgement Committee was 84.0% (63/75) and 80.6% (50/62), respectively, and the effectiveness of SBT/CPZ and CZX as assessed by the attending surgeons was 84.0% (63/75) and 71.0% (44/62), respectively. No significant difference was noted in both assessments. In a total of 36 SBT/CPZ-treated patients with intraabdominal infections, the clinical efficacy was judged by attending surgeons to be excellent in 13 patients (36.1%), and to be excellent or good in 31 (86.1%). In the 30 CZX treated patients, it was judged to be excellent in 6 patients (20.0%), and to be excellent or good in 19 (63.3%). These results presented a significant difference (P |
| doi_str_mv | 10.11553/antibiotics1968b.38.643 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76286438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76286438</sourcerecordid><originalsourceid>FETCH-LOGICAL-j1200-24e45ae66ef6be8e4be6c70ef18384284cbe6d76f1f6ced7fdcf6de771b183f03</originalsourceid><addsrcrecordid>eNpdkctO4zAUhi00iKmgj4Dk1exS4ji13WUI7tQoiavaXIZNlMvJTFAvkLSLeQseGZdWXbDxkfz959PROQhh4o8IGY_pTbHetmW72bZVTyZMlCMqRiykZ2gQEMG8ccj5DzTwKRNewAX5iYZ935Y-JVwEznCBLoLJhLKJP0AfcaIyFUcJjoyRxqQys1hPsXlIbqPYRulNLKd6LhfRi84kVhmOdTqPFsroDD8pO8OOW_Win1X6heeRVc5hDnCujf3qtupxj6cytkpnBt_-wU8ySZwtswudJPIOp9LO9N0VOm-KZQ_DY71ED1Np45mX6N_7Ob1XEvi-F4QQjgtgDBpWgoCwBFZxHxoiqAgDEVbuo-asIQ2roOZNXTWsBs5J6RKNTy_Rr4P3rdu876Df5qu2r2C5LNaw2fU5Z4FwOxUueH0M7soV1Plb166K7n9-XKHj9wf-2m-Lv3DiRefus4T8-7FyKnK6f5z9FKr-FV0Oa_oJ2P2JGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76286438</pqid></control><display><type>article</type><title>CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KOIKE, AKIHIKO ; MASAOKA, AKIRA ; MISHIMA, AKIRA ; MIZUNO, AKIRA ; SUZUKI, HIROSHI ; YURA, JIRO ; MATSUMOTO, KAZUAKI ; IRIYAMA, KEIJI ; KATO, KENICHI ; MATSUMOTO, KOICHI ; TAKESHIGE, KOTOHITO ; KATAOKA, MAKOTO ; ANDO, MASAHIDE ; FUJIOKA, MASAKI ; HORISAWA, MASUMASA ; KOHNO, MEGUMI ; SHINAGAWA, NAGAO ; OGAWA, NOBUYA ; ISHIKAWA, SHU ; ITO, TADAO ; KONDO, TATSUHEI</creator><creatorcontrib>KOIKE, AKIHIKO ; MASAOKA, AKIRA ; MISHIMA, AKIRA ; MIZUNO, AKIRA ; SUZUKI, HIROSHI ; YURA, JIRO ; MATSUMOTO, KAZUAKI ; IRIYAMA, KEIJI ; KATO, KENICHI ; MATSUMOTO, KOICHI ; TAKESHIGE, KOTOHITO ; KATAOKA, MAKOTO ; ANDO, MASAHIDE ; FUJIOKA, MASAKI ; HORISAWA, MASUMASA ; KOHNO, MEGUMI ; SHINAGAWA, NAGAO ; OGAWA, NOBUYA ; ISHIKAWA, SHU ; ITO, TADAO ; KONDO, TATSUHEI</creatorcontrib><description>The clinical effectiveness in postoperative infections of sulbactam/cefoperazone (SBT/CPZ,(SBT 0.5g+CPZ 0.5g)×2/day) was compared to that of ceftizoxime (CZX, 1.0g×2/day) by a well controlled comparative study, to have the following results. 1. The overall effectiveness rate of SBT/CPZ and CZX as judged by Judgement Committee was 84.0% (63/75) and 80.6% (50/62), respectively, and the effectiveness of SBT/CPZ and CZX as assessed by the attending surgeons was 84.0% (63/75) and 71.0% (44/62), respectively. No significant difference was noted in both assessments. In a total of 36 SBT/CPZ-treated patients with intraabdominal infections, the clinical efficacy was judged by attending surgeons to be excellent in 13 patients (36.1%), and to be excellent or good in 31 (86.1%). In the 30 CZX treated patients, it was judged to be excellent in 6 patients (20.0%), and to be excellent or good in 19 (63.3%). These results presented a significant difference (P<0.05, U-test) between the 2 drug groups. 2. The final global improvement ratio judged by attending surgeons was 85.3% (64/75) for SBT/CPZ, and 79.0% (49/62) for CZX with no significant difference. In assessment of time-course improvement, the improvement ratio of SBT/CPZ on day 4 was significantly better than that of CZX (P<0.05, U-test). 3. The usefulness rate of SBT/CPZ and CZX was 84.0% (63/75) and 73.0% (46/63), respectively. There was no significant difference between the 2 drug groups. 4. To assess the bacteriological efficacy, the eradication rate of SBT/CPZ was compared to that of CZX. There was no significant difference between 85.7% (36/42) for SBT/CPZ and 73.5% (25/34) for CZX. 5. After SBT/CPZ administration, 2 patients (2.5%) complained of side effects. In the clinical labolatory tests, abnormality related to SBT/CPZ medication was observed in 6 patients (7.5%), and that related to CZX, in 5 patients (6.4%). As to the types of side effects and frequency, no significant difference was observed between SBT/CPZ and CZX. It is concluded from the above assessments that SBT/CPZ is a useful drug in the treatment of post-operative infections.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.38.643</identifier><identifier>PMID: 2993690</identifier><language>jpn</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Adolescent ; Adult ; Aged ; beta-Lactamase Inhibitors ; Cefoperazone - administration & dosage ; Cefoperazone - therapeutic use ; Cefotaxime - analogs & derivatives ; Cefotaxime - therapeutic use ; Ceftizoxime ; Clinical Trials as Topic ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Infusions, Parenteral ; Male ; Middle Aged ; Penicillanic Acid - administration & dosage ; Penicillanic Acid - therapeutic use ; Sulbactam ; Surgical Wound Infection - drug therapy</subject><ispartof>The Japanese Journal of Antibiotics, 1985/03/25, Vol.38(3), pp.643-670</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2993690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOIKE, AKIHIKO</creatorcontrib><creatorcontrib>MASAOKA, AKIRA</creatorcontrib><creatorcontrib>MISHIMA, AKIRA</creatorcontrib><creatorcontrib>MIZUNO, AKIRA</creatorcontrib><creatorcontrib>SUZUKI, HIROSHI</creatorcontrib><creatorcontrib>YURA, JIRO</creatorcontrib><creatorcontrib>MATSUMOTO, KAZUAKI</creatorcontrib><creatorcontrib>IRIYAMA, KEIJI</creatorcontrib><creatorcontrib>KATO, KENICHI</creatorcontrib><creatorcontrib>MATSUMOTO, KOICHI</creatorcontrib><creatorcontrib>TAKESHIGE, KOTOHITO</creatorcontrib><creatorcontrib>KATAOKA, MAKOTO</creatorcontrib><creatorcontrib>ANDO, MASAHIDE</creatorcontrib><creatorcontrib>FUJIOKA, MASAKI</creatorcontrib><creatorcontrib>HORISAWA, MASUMASA</creatorcontrib><creatorcontrib>KOHNO, MEGUMI</creatorcontrib><creatorcontrib>SHINAGAWA, NAGAO</creatorcontrib><creatorcontrib>OGAWA, NOBUYA</creatorcontrib><creatorcontrib>ISHIKAWA, SHU</creatorcontrib><creatorcontrib>ITO, TADAO</creatorcontrib><creatorcontrib>KONDO, TATSUHEI</creatorcontrib><title>CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>The clinical effectiveness in postoperative infections of sulbactam/cefoperazone (SBT/CPZ,(SBT 0.5g+CPZ 0.5g)×2/day) was compared to that of ceftizoxime (CZX, 1.0g×2/day) by a well controlled comparative study, to have the following results. 1. The overall effectiveness rate of SBT/CPZ and CZX as judged by Judgement Committee was 84.0% (63/75) and 80.6% (50/62), respectively, and the effectiveness of SBT/CPZ and CZX as assessed by the attending surgeons was 84.0% (63/75) and 71.0% (44/62), respectively. No significant difference was noted in both assessments. In a total of 36 SBT/CPZ-treated patients with intraabdominal infections, the clinical efficacy was judged by attending surgeons to be excellent in 13 patients (36.1%), and to be excellent or good in 31 (86.1%). In the 30 CZX treated patients, it was judged to be excellent in 6 patients (20.0%), and to be excellent or good in 19 (63.3%). These results presented a significant difference (P<0.05, U-test) between the 2 drug groups. 2. The final global improvement ratio judged by attending surgeons was 85.3% (64/75) for SBT/CPZ, and 79.0% (49/62) for CZX with no significant difference. In assessment of time-course improvement, the improvement ratio of SBT/CPZ on day 4 was significantly better than that of CZX (P<0.05, U-test). 3. The usefulness rate of SBT/CPZ and CZX was 84.0% (63/75) and 73.0% (46/63), respectively. There was no significant difference between the 2 drug groups. 4. To assess the bacteriological efficacy, the eradication rate of SBT/CPZ was compared to that of CZX. There was no significant difference between 85.7% (36/42) for SBT/CPZ and 73.5% (25/34) for CZX. 5. After SBT/CPZ administration, 2 patients (2.5%) complained of side effects. In the clinical labolatory tests, abnormality related to SBT/CPZ medication was observed in 6 patients (7.5%), and that related to CZX, in 5 patients (6.4%). As to the types of side effects and frequency, no significant difference was observed between SBT/CPZ and CZX. It is concluded from the above assessments that SBT/CPZ is a useful drug in the treatment of post-operative infections.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>beta-Lactamase Inhibitors</subject><subject>Cefoperazone - administration & dosage</subject><subject>Cefoperazone - therapeutic use</subject><subject>Cefotaxime - analogs & derivatives</subject><subject>Cefotaxime - therapeutic use</subject><subject>Ceftizoxime</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Parenteral</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Penicillanic Acid - administration & dosage</subject><subject>Penicillanic Acid - therapeutic use</subject><subject>Sulbactam</subject><subject>Surgical Wound Infection - drug therapy</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctO4zAUhi00iKmgj4Dk1exS4ji13WUI7tQoiavaXIZNlMvJTFAvkLSLeQseGZdWXbDxkfz959PROQhh4o8IGY_pTbHetmW72bZVTyZMlCMqRiykZ2gQEMG8ccj5DzTwKRNewAX5iYZ935Y-JVwEznCBLoLJhLKJP0AfcaIyFUcJjoyRxqQys1hPsXlIbqPYRulNLKd6LhfRi84kVhmOdTqPFsroDD8pO8OOW_Win1X6heeRVc5hDnCujf3qtupxj6cytkpnBt_-wU8ySZwtswudJPIOp9LO9N0VOm-KZQ_DY71ED1Np45mX6N_7Ob1XEvi-F4QQjgtgDBpWgoCwBFZxHxoiqAgDEVbuo-asIQ2roOZNXTWsBs5J6RKNTy_Rr4P3rdu876Df5qu2r2C5LNaw2fU5Z4FwOxUueH0M7soV1Plb166K7n9-XKHj9wf-2m-Lv3DiRefus4T8-7FyKnK6f5z9FKr-FV0Oa_oJ2P2JGA</recordid><startdate>198503</startdate><enddate>198503</enddate><creator>KOIKE, AKIHIKO</creator><creator>MASAOKA, AKIRA</creator><creator>MISHIMA, AKIRA</creator><creator>MIZUNO, AKIRA</creator><creator>SUZUKI, HIROSHI</creator><creator>YURA, JIRO</creator><creator>MATSUMOTO, KAZUAKI</creator><creator>IRIYAMA, KEIJI</creator><creator>KATO, KENICHI</creator><creator>MATSUMOTO, KOICHI</creator><creator>TAKESHIGE, KOTOHITO</creator><creator>KATAOKA, MAKOTO</creator><creator>ANDO, MASAHIDE</creator><creator>FUJIOKA, MASAKI</creator><creator>HORISAWA, MASUMASA</creator><creator>KOHNO, MEGUMI</creator><creator>SHINAGAWA, NAGAO</creator><creator>OGAWA, NOBUYA</creator><creator>ISHIKAWA, SHU</creator><creator>ITO, TADAO</creator><creator>KONDO, TATSUHEI</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>198503</creationdate><title>CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD</title><author>KOIKE, AKIHIKO ; MASAOKA, AKIRA ; MISHIMA, AKIRA ; MIZUNO, AKIRA ; SUZUKI, HIROSHI ; YURA, JIRO ; MATSUMOTO, KAZUAKI ; IRIYAMA, KEIJI ; KATO, KENICHI ; MATSUMOTO, KOICHI ; TAKESHIGE, KOTOHITO ; KATAOKA, MAKOTO ; ANDO, MASAHIDE ; FUJIOKA, MASAKI ; HORISAWA, MASUMASA ; KOHNO, MEGUMI ; SHINAGAWA, NAGAO ; OGAWA, NOBUYA ; ISHIKAWA, SHU ; ITO, TADAO ; KONDO, TATSUHEI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j1200-24e45ae66ef6be8e4be6c70ef18384284cbe6d76f1f6ced7fdcf6de771b183f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1985</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>beta-Lactamase Inhibitors</topic><topic>Cefoperazone - administration & dosage</topic><topic>Cefoperazone - therapeutic use</topic><topic>Cefotaxime - analogs & derivatives</topic><topic>Cefotaxime - therapeutic use</topic><topic>Ceftizoxime</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Parenteral</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Penicillanic Acid - administration & dosage</topic><topic>Penicillanic Acid - therapeutic use</topic><topic>Sulbactam</topic><topic>Surgical Wound Infection - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOIKE, AKIHIKO</creatorcontrib><creatorcontrib>MASAOKA, AKIRA</creatorcontrib><creatorcontrib>MISHIMA, AKIRA</creatorcontrib><creatorcontrib>MIZUNO, AKIRA</creatorcontrib><creatorcontrib>SUZUKI, HIROSHI</creatorcontrib><creatorcontrib>YURA, JIRO</creatorcontrib><creatorcontrib>MATSUMOTO, KAZUAKI</creatorcontrib><creatorcontrib>IRIYAMA, KEIJI</creatorcontrib><creatorcontrib>KATO, KENICHI</creatorcontrib><creatorcontrib>MATSUMOTO, KOICHI</creatorcontrib><creatorcontrib>TAKESHIGE, KOTOHITO</creatorcontrib><creatorcontrib>KATAOKA, MAKOTO</creatorcontrib><creatorcontrib>ANDO, MASAHIDE</creatorcontrib><creatorcontrib>FUJIOKA, MASAKI</creatorcontrib><creatorcontrib>HORISAWA, MASUMASA</creatorcontrib><creatorcontrib>KOHNO, MEGUMI</creatorcontrib><creatorcontrib>SHINAGAWA, NAGAO</creatorcontrib><creatorcontrib>OGAWA, NOBUYA</creatorcontrib><creatorcontrib>ISHIKAWA, SHU</creatorcontrib><creatorcontrib>ITO, TADAO</creatorcontrib><creatorcontrib>KONDO, TATSUHEI</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOIKE, AKIHIKO</au><au>MASAOKA, AKIRA</au><au>MISHIMA, AKIRA</au><au>MIZUNO, AKIRA</au><au>SUZUKI, HIROSHI</au><au>YURA, JIRO</au><au>MATSUMOTO, KAZUAKI</au><au>IRIYAMA, KEIJI</au><au>KATO, KENICHI</au><au>MATSUMOTO, KOICHI</au><au>TAKESHIGE, KOTOHITO</au><au>KATAOKA, MAKOTO</au><au>ANDO, MASAHIDE</au><au>FUJIOKA, MASAKI</au><au>HORISAWA, MASUMASA</au><au>KOHNO, MEGUMI</au><au>SHINAGAWA, NAGAO</au><au>OGAWA, NOBUYA</au><au>ISHIKAWA, SHU</au><au>ITO, TADAO</au><au>KONDO, TATSUHEI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>1985-03</date><risdate>1985</risdate><volume>38</volume><issue>3</issue><spage>643</spage><epage>670</epage><pages>643-670</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>The clinical effectiveness in postoperative infections of sulbactam/cefoperazone (SBT/CPZ,(SBT 0.5g+CPZ 0.5g)×2/day) was compared to that of ceftizoxime (CZX, 1.0g×2/day) by a well controlled comparative study, to have the following results. 1. The overall effectiveness rate of SBT/CPZ and CZX as judged by Judgement Committee was 84.0% (63/75) and 80.6% (50/62), respectively, and the effectiveness of SBT/CPZ and CZX as assessed by the attending surgeons was 84.0% (63/75) and 71.0% (44/62), respectively. No significant difference was noted in both assessments. In a total of 36 SBT/CPZ-treated patients with intraabdominal infections, the clinical efficacy was judged by attending surgeons to be excellent in 13 patients (36.1%), and to be excellent or good in 31 (86.1%). In the 30 CZX treated patients, it was judged to be excellent in 6 patients (20.0%), and to be excellent or good in 19 (63.3%). These results presented a significant difference (P<0.05, U-test) between the 2 drug groups. 2. The final global improvement ratio judged by attending surgeons was 85.3% (64/75) for SBT/CPZ, and 79.0% (49/62) for CZX with no significant difference. In assessment of time-course improvement, the improvement ratio of SBT/CPZ on day 4 was significantly better than that of CZX (P<0.05, U-test). 3. The usefulness rate of SBT/CPZ and CZX was 84.0% (63/75) and 73.0% (46/63), respectively. There was no significant difference between the 2 drug groups. 4. To assess the bacteriological efficacy, the eradication rate of SBT/CPZ was compared to that of CZX. There was no significant difference between 85.7% (36/42) for SBT/CPZ and 73.5% (25/34) for CZX. 5. After SBT/CPZ administration, 2 patients (2.5%) complained of side effects. In the clinical labolatory tests, abnormality related to SBT/CPZ medication was observed in 6 patients (7.5%), and that related to CZX, in 5 patients (6.4%). As to the types of side effects and frequency, no significant difference was observed between SBT/CPZ and CZX. It is concluded from the above assessments that SBT/CPZ is a useful drug in the treatment of post-operative infections.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>2993690</pmid><doi>10.11553/antibiotics1968b.38.643</doi><tpages>28</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2781 |
| ispartof | The Japanese Journal of Antibiotics, 1985/03/25, Vol.38(3), pp.643-670 |
| issn | 0368-2781 2186-5477 |
| language | jpn |
| recordid | cdi_proquest_miscellaneous_76286438 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged beta-Lactamase Inhibitors Cefoperazone - administration & dosage Cefoperazone - therapeutic use Cefotaxime - analogs & derivatives Cefotaxime - therapeutic use Ceftizoxime Clinical Trials as Topic Double-Blind Method Drug Combinations Female Humans Infusions, Parenteral Male Middle Aged Penicillanic Acid - administration & dosage Penicillanic Acid - therapeutic use Sulbactam Surgical Wound Infection - drug therapy |
| title | CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A34%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CLINICAL%20ASSESSMENT%20OF%20SULBACTAM/CEFOPERAZONE%20IN%20COMPARISON%20WITH%20CEFTIZOXIME%20IN%20PATIENTS%20WITH%20POSTOPERATIVE%20INFECTIONS%20BY%20WELL%20CONTROLLED%20METHOD&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=KOIKE,%20AKIHIKO&rft.date=1985-03&rft.volume=38&rft.issue=3&rft.spage=643&rft.epage=670&rft.pages=643-670&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.38.643&rft_dat=%3Cproquest_pubme%3E76286438%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76286438&rft_id=info:pmid/2993690&rfr_iscdi=true |